TREML1 Inhibitors
Chemical inhibitors of TREML1 function by interfering with various stages of platelet activation and aggregation, a process in which TREML1 is involved. Tirofiban and eptifibatide obstruct the glycoprotein IIb/IIIa receptor, a critical site for platelet clumping. By antagonizing this receptor, they prevent the binding of fibrinogen and von Willebrand factor, which are essential for platelets to link together. Similarly, abciximab, another glycoprotein IIb/IIIa inhibitor, binds to the receptor with high affinity, thereby blocking platelet aggregation. This blockade can effectively reduce the activation of platelets in which TREML1 plays a part.
Other inhibitors target different aspects of platelet function that indirectly affect TREML1 activity. Clopidogrel and ticagrelor inhibit the ADP receptor on platelets, which is pivotal in the activation cascade, ultimately resulting in platelet aggregation. Prasugrel, after being metabolized to its active form, also inhibits the P2Y12 ADP-receptor, thus impeding the activation process. Cilostazol and dipyridamole elevate intracellular cAMP levels, leading to the inhibition of platelet aggregation. By increasing cAMP, these drugs indirectly suppress the signaling pathways in which TREML1 is implicated. Acetylsalicylic acid irrevocably inactivates COX-1, causing a decrease in thromboxane A2 production, which is also a promoter of platelet aggregation. Inhibitors like terutroban block the thromboxane receptor, further preventing platelet clumping. Lastly, vorapaxar obstructs the protease-activated receptor-1 on platelets, reducing the response to thrombin, while rivaroxaban directly inhibits factor Xa, thus diminishing thrombin generation and consequently, the activation of platelets involving TREML1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tirofiban-d6 | 144494-65-5 (unlabeled) | sc-475655 | 1 mg | $450.00 | ||
Tirofiban is an antagonist of the glycoprotein IIb/IIIa receptor, which inhibits platelet aggregation. Since TREML1 is thought to participate in platelet activation and aggregation, blocking this receptor with Tirofiban can inhibit the platelet function associated with TREML1. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Cilostazol is a phosphodiesterase 3 inhibitor that leads to an increase in cAMP in platelets, resulting in the inhibition of platelet aggregation. TREML1 function in platelet activation can be inhibited as a downstream effect of the elevated cAMP levels. | ||||||
S-(+)-Clopidogrel Hydrogen Sulfate | 120202-66-6 | sc-220001 sc-220001A sc-220001B | 100 mg 1 g 5 g | $84.00 $168.00 $571.00 | 1 | |
Clopidogrel is an ADP receptor inhibitor which prevents platelet activation. Since TREML1 is implicated in platelet activation, inhibiting the ADP receptor indirectly reduces the functional activity of TREML1 in the activation of platelets. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
Acetylsalicylic acid irreversibly inhibits COX-1, leading to a decrease in thromboxane A2, a promoter of platelet aggregation. This inhibition can indirectly reduce the activity of TREML1, which is involved in platelet function. | ||||||
Ticagrelor | 274693-27-5 | sc-472972 sc-472972A sc-472972B sc-472972C | 10 mg 25 mg 50 mg 100 mg | $104.00 $228.00 $270.00 $302.00 | ||
Ticagrelor is a reversible antagonist of the P2Y12 ADP-receptor on platelets, inhibiting platelet activation and aggregation. Inhibition of this receptor can indirectly inhibit TREML1 function related to platelet activation. | ||||||
Prasugrel | 150322-43-3 | sc-391536 | 100 mg | $79.00 | ||
Prasugrel is a prodrug that inhibits the P2Y12 ADP-receptor on platelets, thereby inhibiting platelet activation. TREML1 function, which is connected to platelet activation, is thus indirectly inhibited through the inhibition of the P2Y12 receptor. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole is an inhibitor of phosphodiesterase and can increase cAMP in platelets, leading to reduced platelet activation. As TREML1 is associated with platelet function, increased cAMP levels can indirectly inhibit the signaling pathways involving TREML1. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $158.00 | 18 | |
Rivaroxaban is a direct factor Xa inhibitor, which decreases the generation of thrombin. As TREML1 is implicated in platelet activation, and thrombin is a strong platelet activator, inhibiting factor Xa can lead to reduced TREML1-mediated platelet activation. | ||||||